Monocyte-eosinophil signaling axis promotes vaccine-mediated protection against SARS-CoV-2
COVID-19 vaccines provide robust protection against severe disease, hospitalization, and death. Neutralizing antibodies are a strong correlate of protection and can prevent SARS-CoV-2 infection of the lungs. We used a conventional laboratory mouse model combined with high- or low-dose vaccination to understand the early immunological response following SARS-CoV-2 infection in the lungs of vaccinated mice. The lungs of high-dose vaccinated mice were completely protected against SARS-CoV-2 infection whereas low-dose vaccinated mice were partially protected. We observed a greater influx of total monocytes, macrophages, dendritic cells, neutrophils, and eosinophils in the lungs of low-dose vaccinated mice compared to naïve infected mice. The different proportions of innate immune cells in the lungs indicated that infection in low-dose vaccinated mice induces a unique inflammatory environment compared to naïve infected or uninfected mice. A prominent feature of infection of low-dose vaccinated mice was infiltration of eosinophils in the lungs, which we observed across different COVID-19 vaccines and SARS-CoV-2 variants. Single cell transcriptional profiling of lung parenchymal immune cells showed that viral RNA was predominantly associated with eosinophils. Eosinophils from low-dose vaccinated mice were transcriptionally distinct from naïve mice after challenge and showed an IFN-γ biased signature. Further, monocytes from low-dose vaccinated mice expressed eotaxin-2, suggesting a monocyte-eosinophil signaling axis. Antibody mediated depletion of eosinophils in low-dose vaccinated mice resulted in increased virus replication and dissemination in the lungs. These findings demonstrate the protective nature of eosinophils during SARS-CoV-2 infection in the context of vaccination and highlight quantitative and qualitative differences in the immune response in a model for vaccine breakthrough infection.
Authors
- Amanda Metz (ORCID: https://orcid.org/0009-0008-4819-0903)
- Kathryn M. Moore (ORCID: https://orcid.org/0000-0002-8483-1148)
- Bushra Wali (ORCID: https://orcid.org/0000-0001-9278-8744)
- M. Williams (ORCID: https://orcid.org/0000-0001-8271-3394)
- Arash Grakoui (ORCID: https://orcid.org/0000-0002-6002-7518)
- Mehul S. Suthar (ORCID: https://orcid.org/0000-0002-2686-8380)
- Rama Rao Amara (ORCID: https://orcid.org/0000-0002-6309-6797)
- Steven E. Bosinger (ORCID: https://orcid.org/0000-0002-2116-5061)
- Madison Ellis (ORCID: https://orcid.org/0000-0002-0325-5477)
- Meenakshi Kar (ORCID: https://orcid.org/0000-0003-3332-811X)
- Stephanie L. Foster (ORCID: https://orcid.org/0000-0002-3097-1129)
- Jacob E. Kohlmeier (ORCID: https://orcid.org/0000-0002-7209-6641)
- Vineet D. Menachery (ORCID: https://orcid.org/0000-0001-8803-7606)
- Robert A. Seder (ORCID: https://orcid.org/0000-0003-3133-0849)
- Katharine Floyd (ORCID: https://orcid.org/0000-0002-0866-6961)
- Elizabeth J. Elrod (ORCID: https://orcid.org/0000-0003-1236-5309)
- Stacey A. Lapp (ORCID: https://orcid.org/0000-0002-6887-7322)
- Ansa Malik
- Jacob Vander Velden
Institutions
- National Institutes of Health (US)
- Emory University (US)
- Emory and Henry College (US)
- Inflammatory Response Research (United States) (US)
- National Institute of Allergy and Infectious Diseases (US)
- Children's Healthcare of Atlanta (US)
Publication Details
- Journal
- PLoS Pathogens
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1371/journal.ppat.1013752
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00